SlideShare a Scribd company logo
1 of 29
Download to read offline
CytoSorbents Corporation


                             Working to Save Lives
                           Through Blood Purification




               CytoSorbents Investor Short Presentation
                          November 2011
                            OTCBB: CTSO
CytoSorbents
Safe Harbor Statement
   Statements in this presentation regarding CytoSorbents Corporation and its operating
   subsidiary CytoSorbents, Inc that are not historical facts are forward-looking statements
   and are subject to risks and uncertainties that could cause actual future events or
   results to differ materially from such statements. Any such forward-looking statements
   are made pursuant to the safe harbor provisions of the Private Securities Litigation
   Reform Act of 1995. It is routine for our internal projections and expectations to change.
   Although these expectations may change, we are under no obligation to inform you if
   they do. Actual events or results may differ materially from those contained in the
   projections or forward-looking statements. The following factors, among others, could
   cause our actual results to differ materially from those described in a forward-looking
   statement: our history of losses; potential fluctuations in our quarterly and annual
   results; competition, inability to achieve regulatory approval for our device, technology
   systems beyond our control and technology-related defects that could affect the
   companies’ products or reputation; risks related to adverse business conditions; our
   dependence on key employees; competition for qualified personnel; the possible
   unavailability of financing as and if needed; and risks related to protecting our
   intellectual property rights or potential infringement of the intellectual property rights of
   third parties. This list is intended to identify only certain of the principal factors that
   could cause actual results to differ from those discussed in the forward-looking
   statements. Readers are referred to a discussion of important risk factors detailed in the
   Company’s Form 10-K filed with the Securities and Exchange Commission on May 31,
   2011 and other reports and documents filed from time to time by us, which are available
   online at www.sec.gov.


CytoSorbents                                                                                       2
CytoSorbents Overview
      CytoSorbents is a publicly-traded critical care-focused
    device company using blood purification to treat disease,
    with its first European Union approved product, CytoSorb™




CytoSorbents                                                    3
Recent Company Highlights
 • Achieved European CE Mark approval for CytoSorb™ as a first-in-class
   extracorporeal cytokine filter, clinically proven in its European Sepsis
   Trial to reduce key cytokines by 30-50% in critically ill septic shock
   patients

 • In this trial, CytoSorb™ treatment also resulted in statistically significant
   improvement in mortality in patients at high risk of death from sepsis

 • Building CytoSorb™ inventory, manufactured under ISO 13485 Full
   Quality Systems certification

 • Limited-market release of CytoSorb™ in Germany began September
   2011 with modest revenue expected year-end. Full launch: April 2012

 • Reimbursement for CytoSorb™ has been established in Germany

 • Xigris, formerly the only treatment for sepsis, withdrawn from all markets
CytoSorbents                                                                       4
Technology Overview
                  The heart of the technology is a
            biocompatible, highly porous, polymer bead
         that can remove a wide range of toxic substances
                   from blood and fluids based on
                pore capture and surface adsorption




CytoSorbents                                                5
Beads Can Be Used In Many Forms




       Hemoperfusion   “Beads in a Bag”   In-line Filter




CytoSorbents                                               6
CytoSorb Is Our Flagship Product
                       ™



          The cornerstone of our critical care strategy is
                               CytoSorb      ™




               An efficient cytokine filter that can help fight
                “Cytokine Storm” and potentially reduce
                  deadly inflammation and organ injury

CytoSorbents                                                      7
Concept is Simple But Elegant
 The polymer beads are packed into cartridges compatible
  with standard hemodialysis machines or blood pumps

                   • Obtain venous access with temporary dialysis catheter

                   • Pump blood through the cartridge with standard pumps

                   • The polymer beads remove cytokines

                   • “Purified” blood is pumped back into the patient

                   • Can treat 20-30 total blood volumes per 6 hr treatment

                   • Each treatment uses a new cartridge



CytoSorbents                                                             8
CytoSorb Approved For Sale in the E.U.
                  ™


       CytoSorb™ has received European regulatory approval
              under the CE Mark and can now be sold
                  throughout the European Union




                   as an Extracorporeal Cytokine Filter
               to be used whenever cytokines are elevated




CytoSorbents                                                 9
Cytokines: A Dual-Edged Sword
  • Cytokines are small proteins that, in moderation,
    normally help stimulate and regulate the
    immune system. They are required for proper
    immune system function

  • However, in excess, cytokines can cause
    disease

  • But in life-threatening illnesses seen commonly in the ICU, they are
    produced in vast excess, often called “cytokine storm”, and can lead
    to cell death, organ damage, ultimately organ failure and death




CytoSorbents                                                               10
Sepsis is a Worldwide Crisis
     Sepsis is the result of an overzealous immune response
           to infection, causing systemic inflammation

  • Top 10 killer afflicting 18 million people worldwide every year

  • Incidence of sepsis doubled in the past 10 years and is increasing

  • Severe sepsis kills 1 in every 3 despite the best medical treatment.
    Septic shock kills 1 in every 2

  • Kills more people in the U.S. than either heart attacks, strokes, or any
    single type of cancer

  • Only approved product, Xigris, was just removed from all markets
    following its PROWESS SHOCK trial that showed no benefit in mortality


CytoSorbents                                                                   11
Sepsis has two facets but only one is treated
 The infectious insult can be treated with antibiotics/antivirals, but there are
  currently no therapies to treat the immune response and cytokine storm

                            Cytokine Storm
         Pro-Inflammatory                           Anti-inflammatory

      TOXIC




        IN
           SU                                                Death
              L   T               Organ Failure
                                                    Recovery


                       Time (days to weeks)
CytoSorbents                                                                   12
CytoSorb Designed to Fight Cytokine Storm




      TOXIC




         IN
            SU
               L   T
                                     Organ Damage


                       Antibiotics    CytoSorb      Recovery

                                         Time
CytoSorbents                                                   13
CytoSorb European Sepsis Trial
                        ™


   Completed a 43-patient randomized, controlled clinical trial
    to treat patients with severe sepsis or septic shock in the
        setting of acute respiratory distress syndrome/ALI


• Compared standard of care therapy alone with
  standard of care therapy plus CytoSorb™ treatment
  (6 hours a day for 7 consecutive days)

• Two goals of the trial
   • Demonstrate safety of treatment
   • Achieve statistical significance of primary
     endpoint of IL-6 reduction

• Secondary and exploratory endpoints were included to examine effect
  on clinical endpoints like mortality and ventilator dependence

CytoSorbents                                                            14
These Patients Had a High Risk of Death
               These risk factors are predictors of mortality
• All had multiple organ failure
     • Nearly 100% had septic shock
     • 100% had respiratory failure with ~ 65% with Acute Respiratory
       Distress Syndrome (ARDS)
     • ~ 30% had Renal failure

• Roughly half were Age ≥ 65
   • Historically accounts for approximately two-thirds of all sepsis cases
   • Relative risk of death is 13-fold compared to younger population *

• About one-third had extremely high cytokine levels: IL-6†, IL-1ra‡, MCP-1,
  IL-8 others


                                   * Martin GS, Crit Care Med 2006, 34(1):15-21
                                   †
                                     Spittler A, Clin Infect Diseases, 2000, 31:1338-1342
                                   ‡
CytoSorbents                         Pablo R, J Intensive Care Med, 26(2):125-132
                                                                                            15
™
          CytoSorb Treatment was Safe
• No serious device related adverse events in more 300 treatments in
  septic patients in the trial, increasing the total number of safely
                                    ™
  administered human CytoSorb treatments to more than 650

• Treatment was well-tolerated by patients

• No clinically significant change in electrolytes or increase in markers of
  organ injury in nearly completed analysis

• Small reduction in platelets and albumin, common to other extracorporeal
  therapies

• Additional biochemical analysis and other marker removal is still underway




CytoSorbents                                                                   16
CytoSorb Broadly Reduces Cytokines
                         ™




  49.1%                                                                                          36.5%
reduction                                                                                      reduction
 p=0.01*                                                                                        p=0.001




  49.5%                                                                                          30.2%
reduction                                                                                      reduction
 p=0.002                                                                                        p=0.002




               Achieved statistically significant 30-50% reduction in key
           cytokines across the 7-day treatment period. Others are pending
CytoSorbents Electronic Randomization Only: N = 43 (18 treatment; 25 control) *interim/final analysis   17
™
  CytoSorb Reduces 28 and 60-day Mortality in
          Patients with High Cytokines

In patients with very high IL-6 (>1,000 pg/mL) or IL-1ra
  (>16,000 pg/mL) levels:

• CytoSorb™ treatment shows statistically significant reduction in 28-day
  mortality (0% vs 63% control, p=0.03, n=14, 6 treated, 8 control)

• Treatment also shows strong trend to benefit in reduction of 60-day
  mortality (17% vs 63% control, p=0.14, n=14)

• Only 33% of treated patients required
  mechanical ventilator support at the
  end of 28-days, versus approximately
  87% of control patients (p=0.09, n = 14)



CytoSorbents                                                                18
CytoSorb™ Reduces 14-day Mortality in
                  Patients Age ≥ 65
• CytoSorb™ treatment for 7 days shows
  statistically significant reduction in
  14-day mortality (0.0% vs 36% control,
   p=0.05, n=21, 10 treated, 11 control)

• 7 days of treatment was not enough to
  demonstrate 28-day mortality benefit
  (40% vs 45% control; p=0.6, n=21)
  suggesting that longer treatment in this very sick population is needed

• Trend to benefit in:
    • Organ dysfunction as measured by MODS score, improved by 28%
      in treated patients vs 9% control (n=21) during the treatment period

     • Reduced ventilator need at 28-days (60% vs 73% control; n = 21)


CytoSorbents                                                                 19
CytoSorb Now Commercialized
                       ™



•   Focus is on direct sales in Germany

•   Have begun a 3-6 month controlled market release
    of CytoSorb™ in September 2011 in select areas in
    Germany, and plan a broader launch in Q2 2012

•   Expect modest revenue this year (2011)

•   Manufacturing under ISO 13485 is in full swing

•   Reimbursement for CytoSorb™ has been established in Germany

•   Plan to use independent distributors to penetrate rest of Europe



CytoSorbents                                                           20
HemoDefend
           Safeguarding the Quality and
            Safety of the Blood Supply


          HemoDefend is a technology platform not yet approved in the US or EU



CytoSorbents
Transfusions Represents a Big Market
• 15 million pRBCs transfused in the US alone each year
  15 million more other blood product transfusions

• Rate of adverse reactions is 3-4%

• Rate of TRALI is 1:2,000 to 5,000 with 10% deaths

• Exact cause is unknown, but linked to accumulation of
  many substances during storage and degradation of blood cells, as well
  as donor factors
    • Antibodies
    • Cytokines and other inflammatory mediators
    • Bioactive lipids, free hemoglobin
    • Drugs, Foreign antigens

• Ongoing concern that “old blood” is “bad blood” with increased risk of
  adverse events including cardiovascular death
CytoSorbents                                                               22
HemoDefend “Beads in a Bag” Platform
• This is a highly innovative approach that
  is unique to the characteristics of our
  highly biocompatible porous beads

• Beads that remove different substances
  are placed into the bag during bag
  manufacturing

• When blood is added, the neutrally
  buoyant beads distribute uniformly,
  preventing the need to mix the blood

• Purification takes place during blood
  storage – a key to efficiency

• A macrofilter prevents bead escape

• No additional equipment is needed

CytoSorbents                                  23
Removes A Broad Range of Substances
               Antibodies                    Bioactive Lipids




                    Hemoglobin




                                 Cytokines
CytoSorbents                                                    24
HemoDefend Can Be Transformative




   HemoDefend converts a low margin blood storage bag into a
  higher margin, self-contained, “Blood Treatment System” that
            is both cost effective and easy to deploy




CytoSorbents                                                 25
CytoSorbents Has a Robust Pipeline
                        With strong development capabilities
NAME           INDICATION                          DESCRIPTION                                  STATUS

CytoSorb™      Severe sepsis and septic shock      Highly efficient cytokine filter that is     European CE Mark
               ARDS/ acute lung injury             designed to treat cytokine storm and         approved as a cytokine
               Burn and smoke inhalation injury    inflammation                                 filter in cases where
               Trauma                                                                           cytokines are elevated
               Severe acute pancreatitis
               Complications of influenza
               Autoimmune disease flares

CytoSorb™      Cardiac Surgery                     Highly efficient cytokine filter to reduce   Observational human
                                                   cytokine-induced organ injury                study completed
               Protection of organ transplants                                                  Human pilot study
                                                                                                completed

BetaSorb™      Improvement of hemodialysis in      Removal of mid-molecular weight toxins       Four human pilot studies
               end-stage renal disease             that are inefficiently removed by standard   completed
                                                   dialysis

HemoDefend     Purification of blood transfusion   “Beads in a Bag” purification technology     Pre-clinical proof of
               products                                                                         concept completed

CST 101/201    Drug overdose/ Chemotherapy         Efficient single pass removal of drugs and   Pre-clinical proof of
               removal during high dose            certain chemotherapy agents from blood       concept completed
               regional chemotherapy

CST 301        Trauma                              Removal of myoglobin from blood caused       Pre-clinical proof of
                                                   by muscle breakdown and                      concept completed
                                                   rhabdomyolysis in trauma


CytoSorbents                                                                                                            26
CytoSorbents Seeks Strategic Alliances
  CytoSorbents has an active business development program
      seeking partners for its growth technology portfolio

   Potential partners include companies involved in:
       •   Dialysis and renal therapies
       •   Pharmaceuticals
       •   Critical care
       •   Advanced materials
       •   Blood purification

      Partnerships help validate the technology, provide
    resources to further develop products, are a source of
    non-dilutive funding, and are potential M&A candidates

CytoSorbents                                                 27
CytoSorbents Seeks New Investors
     CytoSorbents represents a major potential growth story

• CytoSorb™ addresses the root cause of why many patients die in the ICU
  from a wide range of critical illnesses

• The total addressable market in critical care exceeds $10 billion

• With approval of CytoSorb™, the company is transitioning for the first time
  in its history from a development-stage company to a revenue-based
  company with modest revenue expected in 2011

• The company has a strong IP position with 29 issued patents

• The pipeline for products continues to expand with HemoDefend and
  others, enabling the company to monetize its rich technology portfolio
  while pursuing core applications on its own

CytoSorbents                                                                    28
CytoSorbents Corporation
          CytoSorbents Corporation
          CytoSorbents

                             Working to Save Lives
                                   Through
                              Blood Purification
                                   OTCBB: CTSO


                 Phillip P. Chan, MD, PhD
                    CEO and President
                 7 Deer Park Drive, Suite K
                Monmouth Junction, NJ 08852
                      (732) 329-8885
CytoSorbents     pchan@cytosorbents.com

More Related Content

Viewers also liked

Evaluation 2
Evaluation 2Evaluation 2
Evaluation 2EDPRICE93
 
What Can be Done on 9/11 Day? Unlocking the Potential of Pro Bono "Done-in-a-...
What Can be Done on 9/11 Day? Unlocking the Potential of Pro Bono "Done-in-a-...What Can be Done on 9/11 Day? Unlocking the Potential of Pro Bono "Done-in-a-...
What Can be Done on 9/11 Day? Unlocking the Potential of Pro Bono "Done-in-a-...Yvonne Turner
 
Llmlibraryresearchskills2011
Llmlibraryresearchskills2011Llmlibraryresearchskills2011
Llmlibraryresearchskills2011catherineca
 
Building the Ultimate Human Organisation (ArabNet, Beirut, 2016)
Building the Ultimate Human Organisation (ArabNet, Beirut, 2016)Building the Ultimate Human Organisation (ArabNet, Beirut, 2016)
Building the Ultimate Human Organisation (ArabNet, Beirut, 2016)John Peebles
 
Adding Integer Review
Adding Integer ReviewAdding Integer Review
Adding Integer Reviewlrkohrman
 
Turing Festival 2013: Startup Adventures in America and Scotland
Turing Festival 2013: Startup Adventures in America and ScotlandTuring Festival 2013: Startup Adventures in America and Scotland
Turing Festival 2013: Startup Adventures in America and ScotlandJohn Peebles
 
Robert van den Brink, Energietransitie, 26-10-2011
Robert van den Brink, Energietransitie, 26-10-2011Robert van den Brink, Energietransitie, 26-10-2011
Robert van den Brink, Energietransitie, 26-10-2011KennisKring Amsterdam
 
AVReporter Phoenix Contact Wages Plc
AVReporter Phoenix Contact Wages PlcAVReporter Phoenix Contact Wages Plc
AVReporter Phoenix Contact Wages PlcAvreporter KONsys
 
WePayUI组件设计的秘密
WePayUI组件设计的秘密WePayUI组件设计的秘密
WePayUI组件设计的秘密peun zhang
 
Si duhet ta shikojme/studjojme rrealisht nje statistike ne fushen e transportit
Si duhet ta shikojme/studjojme rrealisht nje statistike ne fushen e transportitSi duhet ta shikojme/studjojme rrealisht nje statistike ne fushen e transportit
Si duhet ta shikojme/studjojme rrealisht nje statistike ne fushen e transportitAlbania Energy Association
 

Viewers also liked (17)

Evaluation 2
Evaluation 2Evaluation 2
Evaluation 2
 
What Can be Done on 9/11 Day? Unlocking the Potential of Pro Bono "Done-in-a-...
What Can be Done on 9/11 Day? Unlocking the Potential of Pro Bono "Done-in-a-...What Can be Done on 9/11 Day? Unlocking the Potential of Pro Bono "Done-in-a-...
What Can be Done on 9/11 Day? Unlocking the Potential of Pro Bono "Done-in-a-...
 
Llmlibraryresearchskills2011
Llmlibraryresearchskills2011Llmlibraryresearchskills2011
Llmlibraryresearchskills2011
 
Cormedix ($CRMD) - Maxim June 2011 Update
Cormedix ($CRMD) - Maxim June 2011 UpdateCormedix ($CRMD) - Maxim June 2011 Update
Cormedix ($CRMD) - Maxim June 2011 Update
 
Building the Ultimate Human Organisation (ArabNet, Beirut, 2016)
Building the Ultimate Human Organisation (ArabNet, Beirut, 2016)Building the Ultimate Human Organisation (ArabNet, Beirut, 2016)
Building the Ultimate Human Organisation (ArabNet, Beirut, 2016)
 
Adding Integer Review
Adding Integer ReviewAdding Integer Review
Adding Integer Review
 
Turing Festival 2013: Startup Adventures in America and Scotland
Turing Festival 2013: Startup Adventures in America and ScotlandTuring Festival 2013: Startup Adventures in America and Scotland
Turing Festival 2013: Startup Adventures in America and Scotland
 
Robert van den Brink, Energietransitie, 26-10-2011
Robert van den Brink, Energietransitie, 26-10-2011Robert van den Brink, Energietransitie, 26-10-2011
Robert van den Brink, Energietransitie, 26-10-2011
 
PPPM Bab 123
PPPM Bab 123PPPM Bab 123
PPPM Bab 123
 
Bio
BioBio
Bio
 
Webinar: Open Quality with Spago4Q
Webinar: Open Quality with Spago4QWebinar: Open Quality with Spago4Q
Webinar: Open Quality with Spago4Q
 
AVReporter Phoenix Contact Wages Plc
AVReporter Phoenix Contact Wages PlcAVReporter Phoenix Contact Wages Plc
AVReporter Phoenix Contact Wages Plc
 
26
2626
26
 
Session 10 – nuclear power
Session 10 – nuclear powerSession 10 – nuclear power
Session 10 – nuclear power
 
TRANSITION REPORT 2013
TRANSITION REPORT 2013TRANSITION REPORT 2013
TRANSITION REPORT 2013
 
WePayUI组件设计的秘密
WePayUI组件设计的秘密WePayUI组件设计的秘密
WePayUI组件设计的秘密
 
Si duhet ta shikojme/studjojme rrealisht nje statistike ne fushen e transportit
Si duhet ta shikojme/studjojme rrealisht nje statistike ne fushen e transportitSi duhet ta shikojme/studjojme rrealisht nje statistike ne fushen e transportit
Si duhet ta shikojme/studjojme rrealisht nje statistike ne fushen e transportit
 

Similar to CytoSorbents Corporation (OTCBB: CTSO) Investor Presentation, November 2011

CytoSorb Presentation_24082023.pptx
CytoSorb Presentation_24082023.pptxCytoSorb Presentation_24082023.pptx
CytoSorb Presentation_24082023.pptxJigar Mehta
 
Vascular graft infection do we need antimicrobial grafts
Vascular graft infection do we need antimicrobial graftsVascular graft infection do we need antimicrobial grafts
Vascular graft infection do we need antimicrobial graftsuvcd
 
KIDNEY TRANSPLANTATION SEMINAR PRESENTATION
KIDNEY TRANSPLANTATION SEMINAR PRESENTATIONKIDNEY TRANSPLANTATION SEMINAR PRESENTATION
KIDNEY TRANSPLANTATION SEMINAR PRESENTATIONfareedresidency
 
concised ppt on cytosorb 1.pptx
concised ppt on cytosorb 1.pptxconcised ppt on cytosorb 1.pptx
concised ppt on cytosorb 1.pptxHima Bindu
 
CTXR Investor Deck 2019
CTXR Investor Deck 2019CTXR Investor Deck 2019
CTXR Investor Deck 2019David South
 
Investor cytori presentation public website 9 9 15_final
Investor cytori presentation public website 9 9 15_finalInvestor cytori presentation public website 9 9 15_final
Investor cytori presentation public website 9 9 15_finalcytoriIR
 
Stem cells now and in the future: regulation in Australia
Stem cells now and in the future: regulation in AustraliaStem cells now and in the future: regulation in Australia
Stem cells now and in the future: regulation in AustraliaTGA Australia
 
The Biochip Technology
The Biochip TechnologyThe Biochip Technology
The Biochip Technologyrajatjaiswal48
 
The regulation of biologicals in Australia
The regulation of biologicals in AustraliaThe regulation of biologicals in Australia
The regulation of biologicals in AustraliaTGA Australia
 
Effect of antibiotics.pdf
Effect of antibiotics.pdfEffect of antibiotics.pdf
Effect of antibiotics.pdfJNVSPrince
 
Telomere Analysis in the areas of Inflammation, Arthritis and Exercise
Telomere Analysis in the areas of Inflammation, Arthritis and ExerciseTelomere Analysis in the areas of Inflammation, Arthritis and Exercise
Telomere Analysis in the areas of Inflammation, Arthritis and ExerciseLife Length
 
WOUND AND RECENT MANAGEMENT TRENDS
WOUND AND RECENT MANAGEMENT TRENDSWOUND AND RECENT MANAGEMENT TRENDS
WOUND AND RECENT MANAGEMENT TRENDSRobal Lacoul
 

Similar to CytoSorbents Corporation (OTCBB: CTSO) Investor Presentation, November 2011 (20)

CytoSorb Presentation_24082023.pptx
CytoSorb Presentation_24082023.pptxCytoSorb Presentation_24082023.pptx
CytoSorb Presentation_24082023.pptx
 
Vascular graft infection do we need antimicrobial grafts
Vascular graft infection do we need antimicrobial graftsVascular graft infection do we need antimicrobial grafts
Vascular graft infection do we need antimicrobial grafts
 
KIDNEY TRANSPLANTATION SEMINAR PRESENTATION
KIDNEY TRANSPLANTATION SEMINAR PRESENTATIONKIDNEY TRANSPLANTATION SEMINAR PRESENTATION
KIDNEY TRANSPLANTATION SEMINAR PRESENTATION
 
biomarker in sepsis.pptx
biomarker in sepsis.pptxbiomarker in sepsis.pptx
biomarker in sepsis.pptx
 
concised ppt on cytosorb 1.pptx
concised ppt on cytosorb 1.pptxconcised ppt on cytosorb 1.pptx
concised ppt on cytosorb 1.pptx
 
CTXR Investor Deck 2019
CTXR Investor Deck 2019CTXR Investor Deck 2019
CTXR Investor Deck 2019
 
PPT_Chapter32 B
PPT_Chapter32                                 BPPT_Chapter32                                 B
PPT_Chapter32 B
 
Cytokines
CytokinesCytokines
Cytokines
 
AVICureBiosciencePPT4
AVICureBiosciencePPT4AVICureBiosciencePPT4
AVICureBiosciencePPT4
 
Clinimacs Newsletter 2010
Clinimacs Newsletter 2010Clinimacs Newsletter 2010
Clinimacs Newsletter 2010
 
Investor cytori presentation public website 9 9 15_final
Investor cytori presentation public website 9 9 15_finalInvestor cytori presentation public website 9 9 15_final
Investor cytori presentation public website 9 9 15_final
 
Complement Dependent Cytotoxicity (CDC) cross match test
Complement Dependent Cytotoxicity (CDC) cross match testComplement Dependent Cytotoxicity (CDC) cross match test
Complement Dependent Cytotoxicity (CDC) cross match test
 
Stem cells now and in the future: regulation in Australia
Stem cells now and in the future: regulation in AustraliaStem cells now and in the future: regulation in Australia
Stem cells now and in the future: regulation in Australia
 
The Biochip Technology
The Biochip TechnologyThe Biochip Technology
The Biochip Technology
 
The regulation of biologicals in Australia
The regulation of biologicals in AustraliaThe regulation of biologicals in Australia
The regulation of biologicals in Australia
 
Effect of antibiotics.pdf
Effect of antibiotics.pdfEffect of antibiotics.pdf
Effect of antibiotics.pdf
 
Telomere Analysis in the areas of Inflammation, Arthritis and Exercise
Telomere Analysis in the areas of Inflammation, Arthritis and ExerciseTelomere Analysis in the areas of Inflammation, Arthritis and Exercise
Telomere Analysis in the areas of Inflammation, Arthritis and Exercise
 
WOUND AND RECENT MANAGEMENT TRENDS
WOUND AND RECENT MANAGEMENT TRENDSWOUND AND RECENT MANAGEMENT TRENDS
WOUND AND RECENT MANAGEMENT TRENDS
 
Biofilms.pdf
Biofilms.pdfBiofilms.pdf
Biofilms.pdf
 
Mesenchymal Stem Cell & COVID19
Mesenchymal Stem Cell & COVID19Mesenchymal Stem Cell & COVID19
Mesenchymal Stem Cell & COVID19
 

More from ProActive Capital Resources Group

More from ProActive Capital Resources Group (20)

Pegasi Energy Research Note July 18, 2012
Pegasi Energy Research Note July 18, 2012Pegasi Energy Research Note July 18, 2012
Pegasi Energy Research Note July 18, 2012
 
Islet defense in bio century week of 5 28-12
Islet defense in bio century week of 5 28-12Islet defense in bio century week of 5 28-12
Islet defense in bio century week of 5 28-12
 
Insider transaction detail for Isa Odidi (IPCI)
Insider transaction detail for Isa Odidi (IPCI)Insider transaction detail for Isa Odidi (IPCI)
Insider transaction detail for Isa Odidi (IPCI)
 
Caprock risk management, llc
Caprock risk management, llcCaprock risk management, llc
Caprock risk management, llc
 
VTUS SEC Filing Form 8-K
VTUS SEC Filing Form 8-KVTUS SEC Filing Form 8-K
VTUS SEC Filing Form 8-K
 
TNXP Fact Sheet May 2012
TNXP Fact Sheet May 2012TNXP Fact Sheet May 2012
TNXP Fact Sheet May 2012
 
Arcis Exec Summary
Arcis Exec Summary Arcis Exec Summary
Arcis Exec Summary
 
SSIE 4.20.12
SSIE 4.20.12 SSIE 4.20.12
SSIE 4.20.12
 
Kerx zerenex phase3
Kerx zerenex phase3Kerx zerenex phase3
Kerx zerenex phase3
 
ARM Stroke
ARM StrokeARM Stroke
ARM Stroke
 
ARM Parkinsons
ARM ParkinsonsARM Parkinsons
ARM Parkinsons
 
ARM Heart Disease
ARM Heart DiseaseARM Heart Disease
ARM Heart Disease
 
ARM Diabetes
ARM DiabetesARM Diabetes
ARM Diabetes
 
Arm ALS
Arm ALSArm ALS
Arm ALS
 
Tonix12 ceocfo-article-clean newphoto
Tonix12 ceocfo-article-clean newphotoTonix12 ceocfo-article-clean newphoto
Tonix12 ceocfo-article-clean newphoto
 
Applied DNA Sciences (OTCBB: APDN)
Applied DNA Sciences (OTCBB: APDN)Applied DNA Sciences (OTCBB: APDN)
Applied DNA Sciences (OTCBB: APDN)
 
Daily Dose Equities - Intracoronary Bone Marrow
Daily Dose Equities - Intracoronary Bone MarrowDaily Dose Equities - Intracoronary Bone Marrow
Daily Dose Equities - Intracoronary Bone Marrow
 
Daily Dose Equities - Effect of Transendocardial Delivery
Daily Dose Equities - Effect of Transendocardial Delivery Daily Dose Equities - Effect of Transendocardial Delivery
Daily Dose Equities - Effect of Transendocardial Delivery
 
Daily Dose Equities - Exosomes from human cd34
Daily Dose Equities - Exosomes from human cd34Daily Dose Equities - Exosomes from human cd34
Daily Dose Equities - Exosomes from human cd34
 
2012 MHCC Web resentation proposal-3-19-2012-published
2012 MHCC Web resentation proposal-3-19-2012-published2012 MHCC Web resentation proposal-3-19-2012-published
2012 MHCC Web resentation proposal-3-19-2012-published
 

Recently uploaded

Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Call Girls Service Surat Samaira ❤️🍑 8250192130 👄 Independent Escort Service ...
Call Girls Service Surat Samaira ❤️🍑 8250192130 👄 Independent Escort Service ...Call Girls Service Surat Samaira ❤️🍑 8250192130 👄 Independent Escort Service ...
Call Girls Service Surat Samaira ❤️🍑 8250192130 👄 Independent Escort Service ...CALL GIRLS
 
Call Girls Colaba Mumbai ❤️ 9920874524 👈 Cash on Delivery
Call Girls Colaba Mumbai ❤️ 9920874524 👈 Cash on DeliveryCall Girls Colaba Mumbai ❤️ 9920874524 👈 Cash on Delivery
Call Girls Colaba Mumbai ❤️ 9920874524 👈 Cash on Deliverynehamumbai
 
VIP Russian Call Girls in Varanasi Samaira 8250192130 Independent Escort Serv...
VIP Russian Call Girls in Varanasi Samaira 8250192130 Independent Escort Serv...VIP Russian Call Girls in Varanasi Samaira 8250192130 Independent Escort Serv...
VIP Russian Call Girls in Varanasi Samaira 8250192130 Independent Escort Serv...Neha Kaur
 
Lucknow Call girls - 8800925952 - 24x7 service with hotel room
Lucknow Call girls - 8800925952 - 24x7 service with hotel roomLucknow Call girls - 8800925952 - 24x7 service with hotel room
Lucknow Call girls - 8800925952 - 24x7 service with hotel roomdiscovermytutordmt
 
(Rocky) Jaipur Call Girl - 9521753030 Escorts Service 50% Off with Cash ON De...
(Rocky) Jaipur Call Girl - 9521753030 Escorts Service 50% Off with Cash ON De...(Rocky) Jaipur Call Girl - 9521753030 Escorts Service 50% Off with Cash ON De...
(Rocky) Jaipur Call Girl - 9521753030 Escorts Service 50% Off with Cash ON De...indiancallgirl4rent
 
Call Girls Ooty Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ooty Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Ooty Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ooty Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Call Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls Jaipur
Call Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls JaipurCall Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls Jaipur
Call Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls Jaipurparulsinha
 
VIP Mumbai Call Girls Hiranandani Gardens Just Call 9920874524 with A/C Room ...
VIP Mumbai Call Girls Hiranandani Gardens Just Call 9920874524 with A/C Room ...VIP Mumbai Call Girls Hiranandani Gardens Just Call 9920874524 with A/C Room ...
VIP Mumbai Call Girls Hiranandani Gardens Just Call 9920874524 with A/C Room ...Garima Khatri
 
Call Girls Aurangabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Aurangabad Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Aurangabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Aurangabad Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Call Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Top Rated Bangalore Call Girls Richmond Circle ⟟ 8250192130 ⟟ Call Me For Gen...
Top Rated Bangalore Call Girls Richmond Circle ⟟ 8250192130 ⟟ Call Me For Gen...Top Rated Bangalore Call Girls Richmond Circle ⟟ 8250192130 ⟟ Call Me For Gen...
Top Rated Bangalore Call Girls Richmond Circle ⟟ 8250192130 ⟟ Call Me For Gen...narwatsonia7
 
Vip Call Girls Anna Salai Chennai 👉 8250192130 ❣️💯 Top Class Girls Available
Vip Call Girls Anna Salai Chennai 👉 8250192130 ❣️💯 Top Class Girls AvailableVip Call Girls Anna Salai Chennai 👉 8250192130 ❣️💯 Top Class Girls Available
Vip Call Girls Anna Salai Chennai 👉 8250192130 ❣️💯 Top Class Girls AvailableNehru place Escorts
 
High Profile Call Girls Coimbatore Saanvi☎️ 8250192130 Independent Escort Se...
High Profile Call Girls Coimbatore Saanvi☎️  8250192130 Independent Escort Se...High Profile Call Girls Coimbatore Saanvi☎️  8250192130 Independent Escort Se...
High Profile Call Girls Coimbatore Saanvi☎️ 8250192130 Independent Escort Se...narwatsonia7
 
Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...
Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...
Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...astropune
 
Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...
Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...
Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...Dipal Arora
 
Call Girls Cuttack Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Cuttack Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Cuttack Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Cuttack Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...hotbabesbook
 
Call Girls Kochi Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Kochi Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Kochi Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Kochi Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 

Recently uploaded (20)

Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
 
Call Girls Service Surat Samaira ❤️🍑 8250192130 👄 Independent Escort Service ...
Call Girls Service Surat Samaira ❤️🍑 8250192130 👄 Independent Escort Service ...Call Girls Service Surat Samaira ❤️🍑 8250192130 👄 Independent Escort Service ...
Call Girls Service Surat Samaira ❤️🍑 8250192130 👄 Independent Escort Service ...
 
Call Girls Colaba Mumbai ❤️ 9920874524 👈 Cash on Delivery
Call Girls Colaba Mumbai ❤️ 9920874524 👈 Cash on DeliveryCall Girls Colaba Mumbai ❤️ 9920874524 👈 Cash on Delivery
Call Girls Colaba Mumbai ❤️ 9920874524 👈 Cash on Delivery
 
Escort Service Call Girls In Sarita Vihar,, 99530°56974 Delhi NCR
Escort Service Call Girls In Sarita Vihar,, 99530°56974 Delhi NCREscort Service Call Girls In Sarita Vihar,, 99530°56974 Delhi NCR
Escort Service Call Girls In Sarita Vihar,, 99530°56974 Delhi NCR
 
VIP Russian Call Girls in Varanasi Samaira 8250192130 Independent Escort Serv...
VIP Russian Call Girls in Varanasi Samaira 8250192130 Independent Escort Serv...VIP Russian Call Girls in Varanasi Samaira 8250192130 Independent Escort Serv...
VIP Russian Call Girls in Varanasi Samaira 8250192130 Independent Escort Serv...
 
Lucknow Call girls - 8800925952 - 24x7 service with hotel room
Lucknow Call girls - 8800925952 - 24x7 service with hotel roomLucknow Call girls - 8800925952 - 24x7 service with hotel room
Lucknow Call girls - 8800925952 - 24x7 service with hotel room
 
(Rocky) Jaipur Call Girl - 9521753030 Escorts Service 50% Off with Cash ON De...
(Rocky) Jaipur Call Girl - 9521753030 Escorts Service 50% Off with Cash ON De...(Rocky) Jaipur Call Girl - 9521753030 Escorts Service 50% Off with Cash ON De...
(Rocky) Jaipur Call Girl - 9521753030 Escorts Service 50% Off with Cash ON De...
 
Call Girls Ooty Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ooty Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Ooty Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ooty Just Call 9907093804 Top Class Call Girl Service Available
 
Call Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls Jaipur
Call Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls JaipurCall Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls Jaipur
Call Girls Service Jaipur Grishma WhatsApp ❤8445551418 VIP Call Girls Jaipur
 
VIP Mumbai Call Girls Hiranandani Gardens Just Call 9920874524 with A/C Room ...
VIP Mumbai Call Girls Hiranandani Gardens Just Call 9920874524 with A/C Room ...VIP Mumbai Call Girls Hiranandani Gardens Just Call 9920874524 with A/C Room ...
VIP Mumbai Call Girls Hiranandani Gardens Just Call 9920874524 with A/C Room ...
 
Call Girls Aurangabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Aurangabad Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Aurangabad Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Aurangabad Just Call 9907093804 Top Class Call Girl Service Available
 
Call Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service Available
 
Top Rated Bangalore Call Girls Richmond Circle ⟟ 8250192130 ⟟ Call Me For Gen...
Top Rated Bangalore Call Girls Richmond Circle ⟟ 8250192130 ⟟ Call Me For Gen...Top Rated Bangalore Call Girls Richmond Circle ⟟ 8250192130 ⟟ Call Me For Gen...
Top Rated Bangalore Call Girls Richmond Circle ⟟ 8250192130 ⟟ Call Me For Gen...
 
Vip Call Girls Anna Salai Chennai 👉 8250192130 ❣️💯 Top Class Girls Available
Vip Call Girls Anna Salai Chennai 👉 8250192130 ❣️💯 Top Class Girls AvailableVip Call Girls Anna Salai Chennai 👉 8250192130 ❣️💯 Top Class Girls Available
Vip Call Girls Anna Salai Chennai 👉 8250192130 ❣️💯 Top Class Girls Available
 
High Profile Call Girls Coimbatore Saanvi☎️ 8250192130 Independent Escort Se...
High Profile Call Girls Coimbatore Saanvi☎️  8250192130 Independent Escort Se...High Profile Call Girls Coimbatore Saanvi☎️  8250192130 Independent Escort Se...
High Profile Call Girls Coimbatore Saanvi☎️ 8250192130 Independent Escort Se...
 
Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...
Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...
Best Rate (Hyderabad) Call Girls Jahanuma ⟟ 8250192130 ⟟ High Class Call Girl...
 
Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...
Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...
Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...
 
Call Girls Cuttack Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Cuttack Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Cuttack Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Cuttack Just Call 9907093804 Top Class Call Girl Service Available
 
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
Night 7k to 12k Chennai City Center Call Girls 👉👉 7427069034⭐⭐ 100% Genuine E...
 
Call Girls Kochi Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Kochi Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Kochi Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Kochi Just Call 9907093804 Top Class Call Girl Service Available
 

CytoSorbents Corporation (OTCBB: CTSO) Investor Presentation, November 2011

  • 1. CytoSorbents Corporation Working to Save Lives Through Blood Purification CytoSorbents Investor Short Presentation November 2011 OTCBB: CTSO CytoSorbents
  • 2. Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiary CytoSorbents, Inc that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actual future events or results to differ materially from such statements. Any such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. It is routine for our internal projections and expectations to change. Although these expectations may change, we are under no obligation to inform you if they do. Actual events or results may differ materially from those contained in the projections or forward-looking statements. The following factors, among others, could cause our actual results to differ materially from those described in a forward-looking statement: our history of losses; potential fluctuations in our quarterly and annual results; competition, inability to achieve regulatory approval for our device, technology systems beyond our control and technology-related defects that could affect the companies’ products or reputation; risks related to adverse business conditions; our dependence on key employees; competition for qualified personnel; the possible unavailability of financing as and if needed; and risks related to protecting our intellectual property rights or potential infringement of the intellectual property rights of third parties. This list is intended to identify only certain of the principal factors that could cause actual results to differ from those discussed in the forward-looking statements. Readers are referred to a discussion of important risk factors detailed in the Company’s Form 10-K filed with the Securities and Exchange Commission on May 31, 2011 and other reports and documents filed from time to time by us, which are available online at www.sec.gov. CytoSorbents 2
  • 3. CytoSorbents Overview CytoSorbents is a publicly-traded critical care-focused device company using blood purification to treat disease, with its first European Union approved product, CytoSorb™ CytoSorbents 3
  • 4. Recent Company Highlights • Achieved European CE Mark approval for CytoSorb™ as a first-in-class extracorporeal cytokine filter, clinically proven in its European Sepsis Trial to reduce key cytokines by 30-50% in critically ill septic shock patients • In this trial, CytoSorb™ treatment also resulted in statistically significant improvement in mortality in patients at high risk of death from sepsis • Building CytoSorb™ inventory, manufactured under ISO 13485 Full Quality Systems certification • Limited-market release of CytoSorb™ in Germany began September 2011 with modest revenue expected year-end. Full launch: April 2012 • Reimbursement for CytoSorb™ has been established in Germany • Xigris, formerly the only treatment for sepsis, withdrawn from all markets CytoSorbents 4
  • 5. Technology Overview The heart of the technology is a biocompatible, highly porous, polymer bead that can remove a wide range of toxic substances from blood and fluids based on pore capture and surface adsorption CytoSorbents 5
  • 6. Beads Can Be Used In Many Forms Hemoperfusion “Beads in a Bag” In-line Filter CytoSorbents 6
  • 7. CytoSorb Is Our Flagship Product ™ The cornerstone of our critical care strategy is CytoSorb ™ An efficient cytokine filter that can help fight “Cytokine Storm” and potentially reduce deadly inflammation and organ injury CytoSorbents 7
  • 8. Concept is Simple But Elegant The polymer beads are packed into cartridges compatible with standard hemodialysis machines or blood pumps • Obtain venous access with temporary dialysis catheter • Pump blood through the cartridge with standard pumps • The polymer beads remove cytokines • “Purified” blood is pumped back into the patient • Can treat 20-30 total blood volumes per 6 hr treatment • Each treatment uses a new cartridge CytoSorbents 8
  • 9. CytoSorb Approved For Sale in the E.U. ™ CytoSorb™ has received European regulatory approval under the CE Mark and can now be sold throughout the European Union as an Extracorporeal Cytokine Filter to be used whenever cytokines are elevated CytoSorbents 9
  • 10. Cytokines: A Dual-Edged Sword • Cytokines are small proteins that, in moderation, normally help stimulate and regulate the immune system. They are required for proper immune system function • However, in excess, cytokines can cause disease • But in life-threatening illnesses seen commonly in the ICU, they are produced in vast excess, often called “cytokine storm”, and can lead to cell death, organ damage, ultimately organ failure and death CytoSorbents 10
  • 11. Sepsis is a Worldwide Crisis Sepsis is the result of an overzealous immune response to infection, causing systemic inflammation • Top 10 killer afflicting 18 million people worldwide every year • Incidence of sepsis doubled in the past 10 years and is increasing • Severe sepsis kills 1 in every 3 despite the best medical treatment. Septic shock kills 1 in every 2 • Kills more people in the U.S. than either heart attacks, strokes, or any single type of cancer • Only approved product, Xigris, was just removed from all markets following its PROWESS SHOCK trial that showed no benefit in mortality CytoSorbents 11
  • 12. Sepsis has two facets but only one is treated The infectious insult can be treated with antibiotics/antivirals, but there are currently no therapies to treat the immune response and cytokine storm Cytokine Storm Pro-Inflammatory Anti-inflammatory TOXIC IN SU Death L T Organ Failure Recovery Time (days to weeks) CytoSorbents 12
  • 13. CytoSorb Designed to Fight Cytokine Storm TOXIC IN SU L T Organ Damage Antibiotics CytoSorb Recovery Time CytoSorbents 13
  • 14. CytoSorb European Sepsis Trial ™ Completed a 43-patient randomized, controlled clinical trial to treat patients with severe sepsis or septic shock in the setting of acute respiratory distress syndrome/ALI • Compared standard of care therapy alone with standard of care therapy plus CytoSorb™ treatment (6 hours a day for 7 consecutive days) • Two goals of the trial • Demonstrate safety of treatment • Achieve statistical significance of primary endpoint of IL-6 reduction • Secondary and exploratory endpoints were included to examine effect on clinical endpoints like mortality and ventilator dependence CytoSorbents 14
  • 15. These Patients Had a High Risk of Death These risk factors are predictors of mortality • All had multiple organ failure • Nearly 100% had septic shock • 100% had respiratory failure with ~ 65% with Acute Respiratory Distress Syndrome (ARDS) • ~ 30% had Renal failure • Roughly half were Age ≥ 65 • Historically accounts for approximately two-thirds of all sepsis cases • Relative risk of death is 13-fold compared to younger population * • About one-third had extremely high cytokine levels: IL-6†, IL-1ra‡, MCP-1, IL-8 others * Martin GS, Crit Care Med 2006, 34(1):15-21 † Spittler A, Clin Infect Diseases, 2000, 31:1338-1342 ‡ CytoSorbents Pablo R, J Intensive Care Med, 26(2):125-132 15
  • 16. CytoSorb Treatment was Safe • No serious device related adverse events in more 300 treatments in septic patients in the trial, increasing the total number of safely ™ administered human CytoSorb treatments to more than 650 • Treatment was well-tolerated by patients • No clinically significant change in electrolytes or increase in markers of organ injury in nearly completed analysis • Small reduction in platelets and albumin, common to other extracorporeal therapies • Additional biochemical analysis and other marker removal is still underway CytoSorbents 16
  • 17. CytoSorb Broadly Reduces Cytokines ™ 49.1% 36.5% reduction reduction p=0.01* p=0.001 49.5% 30.2% reduction reduction p=0.002 p=0.002 Achieved statistically significant 30-50% reduction in key cytokines across the 7-day treatment period. Others are pending CytoSorbents Electronic Randomization Only: N = 43 (18 treatment; 25 control) *interim/final analysis 17
  • 18. ™ CytoSorb Reduces 28 and 60-day Mortality in Patients with High Cytokines In patients with very high IL-6 (>1,000 pg/mL) or IL-1ra (>16,000 pg/mL) levels: • CytoSorb™ treatment shows statistically significant reduction in 28-day mortality (0% vs 63% control, p=0.03, n=14, 6 treated, 8 control) • Treatment also shows strong trend to benefit in reduction of 60-day mortality (17% vs 63% control, p=0.14, n=14) • Only 33% of treated patients required mechanical ventilator support at the end of 28-days, versus approximately 87% of control patients (p=0.09, n = 14) CytoSorbents 18
  • 19. CytoSorb™ Reduces 14-day Mortality in Patients Age ≥ 65 • CytoSorb™ treatment for 7 days shows statistically significant reduction in 14-day mortality (0.0% vs 36% control, p=0.05, n=21, 10 treated, 11 control) • 7 days of treatment was not enough to demonstrate 28-day mortality benefit (40% vs 45% control; p=0.6, n=21) suggesting that longer treatment in this very sick population is needed • Trend to benefit in: • Organ dysfunction as measured by MODS score, improved by 28% in treated patients vs 9% control (n=21) during the treatment period • Reduced ventilator need at 28-days (60% vs 73% control; n = 21) CytoSorbents 19
  • 20. CytoSorb Now Commercialized ™ • Focus is on direct sales in Germany • Have begun a 3-6 month controlled market release of CytoSorb™ in September 2011 in select areas in Germany, and plan a broader launch in Q2 2012 • Expect modest revenue this year (2011) • Manufacturing under ISO 13485 is in full swing • Reimbursement for CytoSorb™ has been established in Germany • Plan to use independent distributors to penetrate rest of Europe CytoSorbents 20
  • 21. HemoDefend Safeguarding the Quality and Safety of the Blood Supply HemoDefend is a technology platform not yet approved in the US or EU CytoSorbents
  • 22. Transfusions Represents a Big Market • 15 million pRBCs transfused in the US alone each year 15 million more other blood product transfusions • Rate of adverse reactions is 3-4% • Rate of TRALI is 1:2,000 to 5,000 with 10% deaths • Exact cause is unknown, but linked to accumulation of many substances during storage and degradation of blood cells, as well as donor factors • Antibodies • Cytokines and other inflammatory mediators • Bioactive lipids, free hemoglobin • Drugs, Foreign antigens • Ongoing concern that “old blood” is “bad blood” with increased risk of adverse events including cardiovascular death CytoSorbents 22
  • 23. HemoDefend “Beads in a Bag” Platform • This is a highly innovative approach that is unique to the characteristics of our highly biocompatible porous beads • Beads that remove different substances are placed into the bag during bag manufacturing • When blood is added, the neutrally buoyant beads distribute uniformly, preventing the need to mix the blood • Purification takes place during blood storage – a key to efficiency • A macrofilter prevents bead escape • No additional equipment is needed CytoSorbents 23
  • 24. Removes A Broad Range of Substances Antibodies Bioactive Lipids Hemoglobin Cytokines CytoSorbents 24
  • 25. HemoDefend Can Be Transformative HemoDefend converts a low margin blood storage bag into a higher margin, self-contained, “Blood Treatment System” that is both cost effective and easy to deploy CytoSorbents 25
  • 26. CytoSorbents Has a Robust Pipeline With strong development capabilities NAME INDICATION DESCRIPTION STATUS CytoSorb™ Severe sepsis and septic shock Highly efficient cytokine filter that is European CE Mark ARDS/ acute lung injury designed to treat cytokine storm and approved as a cytokine Burn and smoke inhalation injury inflammation filter in cases where Trauma cytokines are elevated Severe acute pancreatitis Complications of influenza Autoimmune disease flares CytoSorb™ Cardiac Surgery Highly efficient cytokine filter to reduce Observational human cytokine-induced organ injury study completed Protection of organ transplants Human pilot study completed BetaSorb™ Improvement of hemodialysis in Removal of mid-molecular weight toxins Four human pilot studies end-stage renal disease that are inefficiently removed by standard completed dialysis HemoDefend Purification of blood transfusion “Beads in a Bag” purification technology Pre-clinical proof of products concept completed CST 101/201 Drug overdose/ Chemotherapy Efficient single pass removal of drugs and Pre-clinical proof of removal during high dose certain chemotherapy agents from blood concept completed regional chemotherapy CST 301 Trauma Removal of myoglobin from blood caused Pre-clinical proof of by muscle breakdown and concept completed rhabdomyolysis in trauma CytoSorbents 26
  • 27. CytoSorbents Seeks Strategic Alliances CytoSorbents has an active business development program seeking partners for its growth technology portfolio Potential partners include companies involved in: • Dialysis and renal therapies • Pharmaceuticals • Critical care • Advanced materials • Blood purification Partnerships help validate the technology, provide resources to further develop products, are a source of non-dilutive funding, and are potential M&A candidates CytoSorbents 27
  • 28. CytoSorbents Seeks New Investors CytoSorbents represents a major potential growth story • CytoSorb™ addresses the root cause of why many patients die in the ICU from a wide range of critical illnesses • The total addressable market in critical care exceeds $10 billion • With approval of CytoSorb™, the company is transitioning for the first time in its history from a development-stage company to a revenue-based company with modest revenue expected in 2011 • The company has a strong IP position with 29 issued patents • The pipeline for products continues to expand with HemoDefend and others, enabling the company to monetize its rich technology portfolio while pursuing core applications on its own CytoSorbents 28
  • 29. CytoSorbents Corporation CytoSorbents Corporation CytoSorbents Working to Save Lives Through Blood Purification OTCBB: CTSO Phillip P. Chan, MD, PhD CEO and President 7 Deer Park Drive, Suite K Monmouth Junction, NJ 08852 (732) 329-8885 CytoSorbents pchan@cytosorbents.com